Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...
The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
Shares in Novo Nordisk which competes with Eli Lilly in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, rose nearly 9%.